INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Agios Pharmaceuticals, Inc. and Certain Officers and Directors -- AGIO

NEW YORK, Dec. 16, 2016

At the December 2016 American Society of Hematology meeting, Agios presented new data for its AG-519 molecule, which is in development for treatment of pyruvate kinase deficiency. Agios reported for AG-519 that after the data cut-off, one ongoing serious adverse event of drug related cholestatic hepatitis was reported after a dose of 300 mg. On December 5, 2016, following this news, Agios stock fell over 12% to close at $49.88. Then on December 15, 2016, Agios announced it will no longer develop AG-519, and withdrew its investigational new drug (IND) application following a verbal notification of a clinical hold from the U.S. Food and Drug Administration. Following this news, shares of Agios were down almost 20% on intraday trading on December 16, 2016. To obtain additional information about the investigation, go to:

http://zlk.9nl.com/Agios_AGIO

or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:   
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004           
Tel: (212) 363-7500
Toll Free:  (877) 363-5972
Fax: (212) 363-7171
www.zlk.com